CMP Pharma, Inc.
FDA inspection history in Farmville, North Carolina, 2016 to 2023
- 4
- Form 483s
Every document, by year
- Form 483
2016: two Form 483s; 2018: one Form 483; 2023: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2016–18Three Form 483s, at Farmville, North Carolina.
- 2016The longest 483 on file: 4 observations over 3 pages at Farmville, North Carolina.
- 2023One Form 483, at Farmville, North Carolina.
Cited most
Across all CMP Pharma observations on file
- 21 CFR 211.192Production record review3
- 21 CFR 211.22Responsibilities of quality control unit2
- 21 CFR 314.80(b)Postmarketing reporting of adverse drug experiences2
- 21 CFR 211.100(a)Written procedures; deviations1
- 21 CFR 211.160(b)General requirements1
The complete CMP Pharma file.
All 4 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Farmville, North Carolina
Four Form 483s · 2016 to 2023 · 9 observations
Latest: Form 483, Sep 1, 2023 →
Documents
4 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2023-09-01 | 483 Form 483 | Farmville, North Carolina | 1 | $99 |
| 2018-06-28 | 483 Form 483 | Farmville, North Carolina | 2 | $99 |
| 2016-12-21 | 483 Form 483 | Farmville, North Carolina | 2 | $99 |
| 2016-05-11 | 483 Form 483 | Farmville, North Carolina | 4 | $99 |
Investigators on these documents
FEI number 1050589 · most recent document Sep 1, 2023
About CMP Pharma, Inc.
How many FDA Form 483s has CMP Pharma, Inc. received?
FDA Intel has 4 Form 483s on file for CMP Pharma, Inc.; the most recent is dated Sep 1, 2023.
When was CMP Pharma, Inc. last inspected by FDA?
The most recent FDA inspection document on file for CMP Pharma, Inc. is a Form 483 dated Sep 1, 2023, for the site in Farmville, North Carolina.
What did FDA cite at CMP Pharma, Inc.?
The regulations cited most in the observations on file for CMP Pharma, Inc. are 21 CFR 211.192 (Production record review), 3 times; 21 CFR 211.22 (Responsibilities of quality control unit), 2 times; 21 CFR 314.80(b) (Postmarketing reporting of adverse drug experiences), 2 times.